Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences.
about
Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal modelFailure to induce enhanced protection against tuberculosis by increasing T-cell-dependent interferon-gamma generationExpression library immunization: a road map for discovery of vaccines against infectious diseasesresponses of mycobacterium tuberculosis to growth in the mouse lungEnhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway.Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.Bioinformatics in new generation flavivirus vaccines.ESAT-6 subunit vaccination against Mycobacterium tuberculosisProtection against virulent Mycobacterium avium infection following DNA vaccination with the 35-kilodalton antigen is accompanied by induction of gamma interferon-secreting CD4(+) T cells.DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity.Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.Comparative immune response to PE and PE_PGRS antigens of Mycobacterium tuberculosis.Vaccination with a Sindbis virus-based DNA vaccine expressing antigen 85B induces protective immunity against Mycobacterium tuberculosis.DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosisDNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge.Role of signal sequence in vaccine-induced protection against experimental coccidioidomycosisProtective and therapeutic efficacy of Mycobacterium smegmatis expressing HBHA-hIL12 fusion protein against Mycobacterium tuberculosis in miceSurface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in miceVaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene.The PPE domain of PPE17 is responsible for its surface localization and can be used to express heterologous proteins on the mycobacterial surfaceOn the use of DNA vaccines for the prophylaxis of mycobacterial diseases.Virulence, immunogenicity, and protective efficacy of two recombinant Mycobacterium bovis bacillus Calmette-Guérin strains expressing the antigen ESAT-6 from Mycobacterium tuberculosis.Vector Design for Improved DNA Vaccine Efficacy, Safety and Production.DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice.Design, Construction and Cloning of Truncated ORF2 and tPAsp-PADRE-Truncated ORF2 Gene Cassette From Hepatitis E Virus in the pVAX1 Expression Vector.Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis.Construction and evaluation of the novel DNA vaccine harboring the inhibin α (1-32) and the RF-amide related peptide-3 genes for improving fertility in mice.Analysis of known bacterial protein vaccine antigens reveals biased physical properties and amino acid composition.Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG.Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosisFunctional domains present in the mycobacterial hemagglutinin, HBHAIdentification of New Features from Known Bacterial Protective Vaccine Antigens Enhances Rational Vaccine Design.DNA Vaccine-Encoded Flagellin Can Be Used as an Adjuvant Scaffold to Augment HIV-1 gp41 Membrane Proximal External Region Immunogenicity.Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.
P2860
Q24675231-398E275A-AC2F-4B10-9B17-EBF0D11760EDQ28362814-7B6429FA-F242-48FF-980E-DD1E99CB8065Q33225644-52583780-CA05-475F-8CA3-DDE90C1A3998Q33788098-F7E10250-CF8E-4DCD-94A6-DCD8A6F89569Q33806715-90BA57F3-A50C-4D68-B1E3-172A41A71EECQ33834543-63836316-A842-4A94-8A30-5CD5030F27DAQ33839001-2C7C4DD0-7A73-467D-A040-E9CC1B4ACA27Q34003301-90298CFF-7362-42CD-83F5-48125BB296E6Q34004522-4D3F0634-8D1A-441A-A7F7-4BE803331802Q34004529-8CB60A4C-24DA-42B3-ADB3-7C1F874AE657Q34007101-CDE8C7A9-335F-45DF-A9FC-5CA0CD99682AQ34008969-F1FAA154-2E54-4EBA-AABF-7E2C490D06F5Q34111604-531F0E5F-09EC-4723-8176-07CCC24316E7Q34116255-A4A9ECB6-3129-4445-89B9-C6FE73A1BA13Q34124601-EAD0969A-AA7D-46FB-A11B-B6E581593C79Q34125371-87269C67-577D-414D-AAF4-6997F3362BAAQ34171520-029733BC-BF8B-45B9-968A-127CD6E21D0DQ34309667-A8419F6B-AB99-459A-90DB-1A27B9A43C83Q34326532-F1052949-0266-4AFE-BD03-C894EF662E9EQ34613099-0D7708E8-302F-4636-8378-841490A60D5AQ34852418-61756888-74A9-42DB-B608-13251A5BBB36Q34853792-7134C26A-D3E5-4857-848C-A59665A3CFCCQ35826665-C43E2002-E4E6-4253-BF49-9DEF2648BEFFQ36445502-550728C7-9AEE-45D9-BDEE-F9CD7E5CA204Q36553413-6321A357-35FF-4BDE-AAB7-9916AB2B3E56Q36575310-593FDE7B-B6EC-4323-BB50-F8FD3945E609Q36666321-208F2C15-1D4E-4ACA-8EDF-CC5495AB81E7Q36748424-688722DB-5091-4253-B79E-824A76849AA6Q36978363-518CC074-9B5F-4D8F-AEA4-4727A15C4666Q37398200-CA290A74-8A38-4956-A5A7-816589803F8FQ37624063-EAD8121C-057A-438F-B025-5D1C6B625CECQ39498129-05EE582E-5E15-49F9-90CC-E8A0714E01F3Q44119319-854B4AA4-6724-4A13-8D7F-5610A43CB106Q52729536-6A6CAB12-AE75-47A4-A335-D35F97F334EEQ55432126-2327E5D3-5395-47C5-AEBA-DBC2D50BF272
P2860
Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Immunogenicity of DNA vaccines ...... en activator signal sequences.
@ast
Immunogenicity of DNA vaccines ...... en activator signal sequences.
@en
Immunogenicity of DNA vaccines ...... en activator signal sequences.
@nl
type
label
Immunogenicity of DNA vaccines ...... en activator signal sequences.
@ast
Immunogenicity of DNA vaccines ...... en activator signal sequences.
@en
Immunogenicity of DNA vaccines ...... en activator signal sequences.
@nl
prefLabel
Immunogenicity of DNA vaccines ...... en activator signal sequences.
@ast
Immunogenicity of DNA vaccines ...... en activator signal sequences.
@en
Immunogenicity of DNA vaccines ...... en activator signal sequences.
@nl
P2093
P2860
P1476
Immunogenicity of DNA vaccines ...... en activator signal sequences.
@en
P2093
P2860
P304
P407
P577
1999-09-01T00:00:00Z